Article
Dermatology
Kenneth B. Gordon, Richard G. Langley, Richard B. Warren, Yukari Okubo, Linda Stein Gold, Joseph F. Merola, Luke Peterson, Krista Wixted, Nancy Cross, Delphine Deherder, Diamant Thaci
Summary: The study aimed to evaluate the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis. Pooled analysis of data from 8 clinical trials showed that bimekizumab was well tolerated with an increased incidence of mild to moderate oral candidiasis. No safety signals were observed, and there was no increased risk of adverse events with longer duration of bimekizumab exposure.
Article
Medicine, General & Internal
Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt
Summary: The study demonstrated that Bimekizumab showed high levels of response in patients with moderate to severe plaque psoriasis, with durable effects over 56 weeks under both maintenance dosing schedules (every 4 weeks and every 8 weeks). Additionally, Bimekizumab was well tolerated with no unexpected safety issues, further supporting its therapeutic value for this patient population.
Article
Dermatology
D. Thaci, S. Piaserico, R. B. Warren, A. K. Gupta, W. Cantrell, Z. Draelos, P. Foley, A. Igarashi, R. G. Langley, A. Asahina, M. Young, M. Falques, I. Pau-Charles, A. M. Mendelsohn, S. J. Rozzo, K. Reich
Summary: The research demonstrates that treatment with the anti-interleukin-23p19 monoclonal antibody tildrakizumab provides sustained disease control over 5 years for psoriasis patients, with a reassuring safety profile.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Michael Sticherling, Arjen F. Nikkels, Ashraf M. Hamza, Pearl Kwong, Jacek C. Szepietowski, Mahira El Sayed, Pierre-Dominique Ghislain, Alkes A. Khotko, Manmath Patekar, Christine-Elke Ortmann, Pascal Forrer, Philemon Papanastasiou, Deborah Keefe
Summary: Secukinumab has been shown to be effective and safe in treating moderate to severe plaque psoriasis in pediatric patients. This study reports the safety profile of secukinumab in pediatric patients and compares it with the data from adult patients. The results demonstrate that secukinumab is well tolerated in pediatric patients and the safety profile is consistent with that in adults.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Wang, Christopher Cioffi, Veerle Vanvoorden, Mark Lebwohl
Summary: Bimekizumab was more effective than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis, with a safety profile consistent with previous studies.
Article
Dermatology
Chunlei Zhang, Kexiang Yan, Qingchun Diao, Qing Guo, Hongzhong Jin, Sen Yang, Xiang Chen, Tiechi Lei, Jianhua Wu, Hong Yu, Min Zheng, Xinghua Gao, Rodney Sinclair, Yi Zhu, Qian Xu, Jinhua Xu
Summary: This study evaluated the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis. The results showed that Vunakizumab groups had significantly higher proportions of patients with at least 75% improvement in the Psoriasis Area and Severity Index compared to the placebo group, with no unexpected adverse effects observed. However, the study had limitations such as a relatively short duration and lack of an active control group.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yuqian Wang, Sheng Li, Juan Bai, Xiaoxuan Cai, Shunli Tang, Peiyi Lin, Qingmiao Sun, Jianjun Qiao, Hong Fang
Summary: This study evaluated the efficacy and safety of bimekizumab in treating patients with psoriasis and determined the optimal maintenance dosing schedules. The results showed that bimekizumab had better efficacy than placebo or active comparators in treating psoriasis. After 16 weeks of initial maintenance treatment, both bimekizumab maintenance dosing schedules (320 mg every 4 and 8 weeks) had similar efficacy.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Article
Dermatology
K. Reich, L. Iversen, L. Puig, J. Lambert, U. Mrowietz, K. Kaplan Saday, R. B. Warren
Summary: Treatment with brodalumab resulted in sustained high levels of skin clearance in patients with moderate-to-severe psoriasis, with a high proportion of patients achieving PASI 90 at Week 120. The treatment was well tolerated and had a similar safety profile to previous studies, supporting its long-term efficacy and safety.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Medicine, General & Internal
Ilenia Calcaterra, Roberta Lupoli, Alessandro Di Minno, Matteo Nicola Dario Di Minno
Summary: In patients with severe hypertriglyceridemia, volanesorsen treatment leads to significant reductions in triglyceride levels, VLDL-C levels, Apo-B48 levels, and non-HDL-C levels, while increasing HDL-C levels. The treatment is associated with an acceptable safety profile.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Dermatology
Xiaoying Jia, Yang Zhao, Justin Carrico, Thor-Henrik Brodtkorb, Alan M. Mendelsohn, Simon Lowry, Steve Feldman, Jashin J. Wu, April W. Armstrong
Summary: This study evaluated the relative cost-effectiveness of different biologic and targeted systemic treatments as first-line therapy for moderate-to-severe plaque psoriasis. The results showed that tildrakizumab is one of the most cost-effective treatments for this condition.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Dermatology
Atsuyuki Igarashi, Hidemi Nakagawa, Akimichi Morita, Yukari Okubo, Shigetoshi Sano, Shinichi Imafuku, Yayoi Tada, Masaru Honma, Alan M. Mendelsohn, Masaki Kawamura, Mamitaro Ohtsuki
Summary: Tildrakizumab demonstrated significant efficacy in treating Japanese patients with moderate to severe plaque psoriasis, with a good safety profile and durable response.
JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
H. Hamm, D. Wilsmann-Theis, A. Tsianakas, T. Gambichler, K. Taipale, J. Lauterbach, U. Freudensprung, C. Makepeace
Summary: This study demonstrated that fumaric acid esters (FAE) showed superior treatment response compared to placebo in children and adolescents aged 10-17 with moderate-to-severe psoriasis after 20 weeks, with generally good tolerability. However, further studies are needed to confirm these findings.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Laura Calabrese, Marta Grimaldi, Gaia Moretta, Gianluca Pagnanelli, Ruslana Gaeta Shumak, Marina Talamonti, Lorenzo Tofani, Sabatino Pallotta, Ketty Peris, Concetta Potenza, Clara De Simone, Elena Campione
Summary: The efficacy and safety of tildrakizumab were evaluated in a real-life setting for patients with moderate-to-severe psoriasis over a 28-week treatment period. The results showed that tildrakizumab had high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Gabrielle Becher, Sophia Conner, Jennifer A. Ingram, Karen E. Stephen, Alison C. McInnes, Adrian H. Heald, Paul A. Riley, Mark Davies, Arnau Domenech, Ismail Kasujee
Summary: This retrospective real-world data study conducted in the United Kingdom demonstrates the efficacy and tolerability of tildrakizumab in the treatment of moderate-to-severe plaque psoriasis. Most patients remained on treatment for the duration of the study and achieved significant improvement in disease indicators.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
Eric L. Simpson, Joseph F. Merola, Jonathan Silverberg, Kristian Reich, Richard B. Warren, Delphine Staumont-Salle, Giampiero Girolomoni, Kim Papp, Marjolein de Bruin-Weller, Jacob P. Thyssen, Rebecca Zachariae, Christiana K. Olsen, Andreas Wollenberg
Summary: Tralokinumab, as a fully human monoclonal antibody neutralizing interleukin-13, has shown efficacy and good tolerability in clinical trials involving adults with moderate-to-severe atopic dermatitis (AD). This study analyzed pooled data from phase II and III trials to assess the safety profile of tralokinumab. The results demonstrated that tralokinumab had a similar safety profile to placebo, with no clinically significant changes observed in laboratory measures.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Fiona Lynch, Mary-Catherine Walsh, Muriel Sadlier
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Letter
Dermatology
Anthony Moussa, Samantha Eisman, Ahmed Kazmi, Janina Poa, Vijaya Chitreddy, Deepani Rathnayake, Shobha Joseph, Rodney Daniel Sinclair, Bevin Bhoyrul
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Letter
Dermatology
Anthony Moussa, Samantha Eisman, Rodney Daniel Sinclair, Bevin Bhoyrul
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Dermatology
Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, Anand K. Ganesan, Mauro Picardo, Diamant Thaci, John E. Harris, Jung Min Bae, Katsuhiko Tsukamoto, Rodney Sinclair, Amit G. Pandya, Abigail Sloan, Dahong Yu, Kavita Gandhi, Michael S. Vincent, Brett King
Summary: This study evaluated the efficacy and safety of oral JAK3/TEC inhibitor ritlecitinib in patients with active nonsegmental vitiligo. The results showed that ritlecitinib demonstrated significant efficacy and good tolerability in treating vitiligo.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Dermatology
Anneliese Willems, Anthony Moussa, Rodney Sinclair
Summary: Androgenetic alopecia (AGA) is common and can have significant psychological impacts on Australian men. This study aims to examine the current prescribing patterns of Australian dermatologists for male AGA.
AUSTRALASIAN JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Dermatology
William C. Cranwell, Rodney D. Sinclair
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Dermatology
Leila Asfour, Laita Bokhari, Bevin Bhoyrul, Samantha Eisman, Anthony Moussa, Huw Rees, Rodney D. Sinclair
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Mark G. Lebwohl, Joseph F. Merola, Katelyn Rowland, Megan Miller, Ya-Wen Yang, Jenny Yu, Yin You, Daphne Chan, Diamant Thaci, Richard G. Langley
Summary: This study evaluated the safety of guselkumab in 2891 patients with psoriasis who were treated for up to 5 years. The findings showed that guselkumab demonstrated favorable safety, consistent with previous reports. The safety event rates in guselkumab-treated patients were similar to those observed in the placebo group and remained consistent throughout long-term treatment.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Andrew Blauvelt, Diamant Thaci, Kim A. Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Daphne Chan, Jenny Yu, Ya-Wen Yang, Mark G. Lebwohl, Alice B. Gottlieb, Jeffrey Crowley, Peter Foley
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
A. D. Burden, Y. Okubo, M. Zheng, D. Thaci, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon
Summary: Effisayil 1 was a study investigating the use of spesolimab in patients with a flare-up of generalized pustular psoriasis (GPP). The study found that patients receiving spesolimab showed rapid clearance of pustules and skin symptoms within 1 week. The effectiveness and safety of spesolimab were consistent across different patient demographic and clinical characteristics.
EXPERIMENTAL DERMATOLOGY
(2023)
Review
Ophthalmology
Mahdi Balali-Mood, Rodney D. Sinclair, Emadodin Darchini-Maragheh, Leila Etemad
Summary: Amphetamines, the second most commonly used illicit drug worldwide, can cause significant skin problems. This review focuses on the dermatological manifestations of amphetamine abuse.
CUTANEOUS AND OCULAR TOXICOLOGY
(2023)
Article
Dermatology
Rodney Sinclair, Sammy Sharifeh, Susan Thackwray, Jason Lickliter, Junlong Wu, Jing Li, Bei Qi, Philip Bland-Ward, Harald Reinhart
Summary: ZL-1102, a novel antibody fragment targeting IL-17A, showed good safety, local tolerability, and a trend towards improved local psoriasis area and severity index (PASI) in patients with mild-to-moderate chronic plaque psoriasis (CPP).
EXPERIMENTAL DERMATOLOGY
(2023)
Letter
Dermatology
Orla McFeely, Nekma Meah, Rodney Sinclair, Dmitri Wall
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Article
Oncology
Kim A. Papp, Mark G. Lebwohl, Diamant Thaci, Janusz Jaworski, Bartlomiej Kwiek, Jakub Trefler, Anna Dudek, Jacek C. Szepietowski, Nataliya Reznichenko, Joanna Narbutt, Wojciech Baran, Joanna Kolinek, Stefan Daniluk, Katarzyna Bartnicka-Maslowska, Adam Reich, Yuriy Andrashko, Sunghyun Kim, Yunju Bae, Dabee Jeon, Jinsun Jung, Hyunseung Lee, Tina Pyo, Woori Ko
Summary: CT-P43 demonstrated equivalent efficacy to originator ustekinumab in adults with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety, and immunogenicity profiles.
Article
Dermatology
Maryanne M. Senna, Ohsang Kwon, Bianca M. Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Brett King
Summary: The present study investigates the clinical benefits of baricitinib treatment on scalp hair regrowth, specifically focusing on eyebrow and eyelash hair. The results show that meaningful regrowth in these areas can occur even without complete scalp hair regrowth. Emotional distress and quality of life improvement are most associated with obtaining a clinical meaningful improvement in scalp hair.
DERMATOLOGY AND THERAPY
(2023)